190 related articles for article (PubMed ID: 17825550)
1. Persistent low urinary excretion of 5-HIAA is a marker for favourable survival during follow-up in patients with disseminated midgut carcinoid tumours.
van der Horst-Schrivers AN; Post WJ; Kema IP; Links TP; Willemse PH; Wymenga AN; de Vries EG
Eur J Cancer; 2007 Dec; 43(18):2651-7. PubMed ID: 17825550
[TBL] [Abstract][Full Text] [Related]
2. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.
Turner GB; Johnston BT; McCance DR; McGinty A; Watson RG; Patterson CC; Ardill JE
Gut; 2006 Nov; 55(11):1586-91. PubMed ID: 16556667
[TBL] [Abstract][Full Text] [Related]
3. Description of patients with midgut carcinoid tumours: clinical database from a Danish centre.
Nykjaer KM; Grønbaek H; Nielsen DT; Christiansen P; Astrup LB
In Vivo; 2007; 21(4):679-84. PubMed ID: 17708366
[TBL] [Abstract][Full Text] [Related]
4. Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome.
Swärd C; Johanson V; Nieveen van Dijkum E; Jansson S; Nilsson O; Wängberg B; Ahlman H; Kölby L
Br J Surg; 2009 May; 96(5):517-21. PubMed ID: 19358175
[TBL] [Abstract][Full Text] [Related]
5. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
[TBL] [Abstract][Full Text] [Related]
6. The value of 5-hydroxyindolacetic acid analysis in urine. A clinical and cost-benefit study.
Lasson A; Alwmark A
Ann Chir Gynaecol; 1985; 74(5):219-22. PubMed ID: 2417537
[TBL] [Abstract][Full Text] [Related]
7. 5-HIAA excretion is not associated with bone metabolism in carcinoid syndrome patients.
van Dijk SC; de Herder WW; Kwekkeboom DJ; Zillikens MC; Feelders RA; van Schaik RH; van Driel M; van Leeuwen JP
Bone; 2012 Jun; 50(6):1260-5. PubMed ID: 22425693
[TBL] [Abstract][Full Text] [Related]
8. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.
Kölby L; Persson G; Franzén S; Ahrén B
Br J Surg; 2003 Jun; 90(6):687-93. PubMed ID: 12808615
[TBL] [Abstract][Full Text] [Related]
9. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients.
Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman J; Onaitis MW; Tyler DS; Olson JA
Cancer; 2004 Nov; 101(9):1987-93. PubMed ID: 15455358
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular abnormalities in patients with a carcinoid syndrome.
Meijer WC; van Veldhuisen DJ; Kema IP; Van den Berg MP; Boomsma F; Willemse PH; De Vries EG
Neth J Med; 2002 Mar; 60(1):10-6. PubMed ID: 12074037
[TBL] [Abstract][Full Text] [Related]
11. [Pitfalls in the diagnosis of carcinoids in patients treated with aminosalicylates].
Dastych M; Dastych M; Zboril V; Senkyrík M; Starý K; Cáslavský J; Chmelík J
Vnitr Lek; 2003 Mar; 49(3):200-4. PubMed ID: 12733495
[TBL] [Abstract][Full Text] [Related]
12. Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction.
Wängberg B; Westberg G; Tylén U; Tisell L; Jansson S; Nilsson O; Johansson V; Scherstén T; Ahlman H
World J Surg; 1996 Sep; 20(7):892-9; discussion 899. PubMed ID: 8678968
[TBL] [Abstract][Full Text] [Related]
13. Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study.
Jacobsen MB; Hanssen LE; Kolmannskog F; Schrumpf E; Vatn MH; Bergan A
Scand J Gastroenterol; 1995 Aug; 30(8):789-96. PubMed ID: 7481548
[TBL] [Abstract][Full Text] [Related]
14. HPLC-mass spectrometry method for quantitative detection of neuroendocrine tumor markers: vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid.
Lionetto L; Lostia AM; Stigliano A; Cardelli P; Simmaco M
Clin Chim Acta; 2008 Dec; 398(1-2):53-6. PubMed ID: 18760269
[TBL] [Abstract][Full Text] [Related]
15. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor.
Zuetenhorst JM; Bonfrer JM; Korse CM; Bakker R; van Tinteren H; Taal BG
Cancer; 2003 Apr; 97(7):1609-15. PubMed ID: 12655516
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of cyclooxygenase-2 as a prognostic biomarker in mid-gut carcinoid tumours.
Cadden I; Johnston BT; Turner G; McCance D; Ardill J; McGinty A
Neuroendocrinology; 2007; 86(2):104-11. PubMed ID: 17700013
[TBL] [Abstract][Full Text] [Related]
17. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
Tellez MR; Mamikunian G; O'Dorisio TM; Vinik AI; Woltering EA
Pancreas; 2013 Apr; 42(3):405-10. PubMed ID: 23160483
[TBL] [Abstract][Full Text] [Related]
18. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours.
Zandee WT; Kamp K; van Adrichem RC; Feelders RA; de Herder WW
Eur J Endocrinol; 2016 Nov; 175(5):361-6. PubMed ID: 27491374
[TBL] [Abstract][Full Text] [Related]
19. Pre- and postoperative levels in serum of mannan-binding lectin associated serine protease-2 -a prognostic marker in colorectal cancer.
Ytting H; Christensen IJ; Thiel S; Jensenius JC; Nielsen HJ
Hum Immunol; 2008 Jul; 69(7):414-20. PubMed ID: 18638656
[TBL] [Abstract][Full Text] [Related]
20. Midgut carcinoid tumours: surgical treatment and prognosis.
Kerström G; Hellman P; Hessman O
Best Pract Res Clin Gastroenterol; 2005 Oct; 19(5):717-28. PubMed ID: 16253896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
